Downregulation of FoxM1 sensitizes nasopharyngeal carcinoma cells to cisplatin via inhibition of MRN-ATM-mediated DNA repair
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Chemoresistance is the primary obstacle in the treatment of locally advanced and metastatic nasopharyngeal carcinoma (NPC). Recent evidence suggests that the transcription factor forkhead box M1 (FoxM1) is involved in chemoresistance. Our group previously confirmed that FoxM1 is overexpressed in NPC. In this study, we investigated the role of FoxM1 in cisplatin resistance of the cell lines 5-8F and HONE-1 and explored its possible mechanism. Our results showed that FoxM1 and NBS1 were both overexpressed in NPC tissues based on data from the GSE cohort (GSE12452). Then, we measured FoxM1 levels in NPC cells and found FoxM1 was overexpressed in NPC cell lines and could be stimulated by cisplatin. MTT and clonogenic assays, flow cytometry, H2AX immunofluorescence, qRT-PCR, and western blotting revealed that downregulation of FoxM1 sensitized NPC cells to cisplatin and reduced the repair of cisplatin-induced DNA double-strand breaks via inhibition of the MRN (MRE11-RAD50-NBS1)-ATM axis, which might be related to the ability of FoxM1 to regulate NBS1. Subsequently, we demonstrated that enhanced sensitivity of FoxM1 knockdown cells could be reduced by overexpression of NBS1. Taken together, our data demonstrate that downregulation of FoxM1 could improve the sensitivity of NPC cells to cisplatin through inhibition of MRN-ATM-mediated DNA repair, which could be related to FoxM1-dependent regulation of NBS1.
Abstract
Chemoresistance is the primary obstacle in the treatment of locally advanced and metastatic nasopharyngeal carcinoma (NPC). Recent evidence suggests that the transcription factor forkhead box M1 (FoxM1) is involved in chemoresistance. Our group previously confirmed that FoxM1 is overexpressed in NPC. In this study, we investigated the role of FoxM1 in cisplatin resistance of the cell lines 5-8F and HONE-1 and explored its possible mechanism. Our results showed that FoxM1 and NBS1 were both overexpressed in NPC tissues based on data from the GSE cohort (GSE12452). Then, we measured FoxM1 levels in NPC cells and found FoxM1 was overexpressed in NPC cell lines and could be stimulated by cisplatin. MTT and clonogenic assays, flow cytometry, H2AX immunofluorescence, qRT-PCR, and western blotting revealed that downregulation of FoxM1 sensitized NPC cells to cisplatin and reduced the repair of cisplatin-induced DNA double-strand breaks via inhibition of the MRN (MRE11-RAD50-NBS1)-ATM axis, which might be related to the ability of FoxM1 to regulate NBS1. Subsequently, we demonstrated that enhanced sensitivity of FoxM1 knockdown cells could be reduced by overexpression of NBS1. Taken together, our data demonstrate that downregulation of FoxM1 could improve the sensitivity of NPC cells to cisplatin through inhibition of MRN-ATM-mediated DNA repair, which could be related to FoxM1-dependent regulation of NBS1.
참고문헌 (30)
- Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
- Al-Sarraf M, "Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer : phase III randomized Intergroup study 0099", J Clin Oncol, 16, pp.1310~1317 (1998)
- Yoshizaki T, "Progress and controversy for the role of chemotherapy in nasopharyngeal carcinoma", Jpn J Clin Oncol, 45, pp.244~247 (2015)
- Lee AW, "Treatment results for nasopharyngeal carcinoma in the modern era : the Hong Kong experience", Int J Radiat Oncol Biol Phys, 61, pp.1107~1116 (2005)
- Lee AW, "Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985 : overall survival and patterns of failure", Int J Radiat Oncol Biol Phys, 23, pp.261~270 (1992)
- Galluzzi L, "Molecular mechanisms of cisplatin resistance", Oncogene, 31, pp.1869~1883 (2012)
- Goldstein M, "The DNA damage response : implications for tumor responses to radiation and chemotherapy", Annu Rev Med, 66, pp.129~143 (2015)
- Paull TT, "The Mre11", Rad50, Cell Cycle, pp.2005, 4[DOI]
- Frappart PO, "An essential function for NBS1 in the prevention of ataxia and cerebellar defects", Nat Med, 11, pp.538~544 (2005)
- So S, "Autophosphorylation at serine 1981 stabilizes ATM at DNA damage sites", J Cell Biol, 187, pp.977~990 (2009)
- Lamarche BJ, "The MRN complex in double-strand break repair and telomere maintenance", FEBS Lett, 584, pp.3682~3695 (2010)
- Laoukili J, "FoxM1 : at the crossroads of ageing and cancer", Biochim Biophys Acta, 1775, pp.92~102 (2007)
- Koo CY, "FOXM1 : From cancer initiation to progression and treatment", Biochim Biophys Acta, 1819, pp.28~37 (2012)
- Zhou J, "FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer", PLoS One, 9, pp.e96989~ (2014)
- Park YY, "FOXM1mediates Dox resistance in breast cancer by enhancing DNA repair", Carcinogenesis, 33, pp.1843~1853 (2012)
- Chua MLK, "Nasopharyngeal carcinoma", Lancet, 387, pp.1012~1024 (2016)
- Kuo LJ, "Gamma-H2AX-a novel biomarker for DNA double-strand breaks", In Vivo, 22, pp.305~309 (2008)
- Wang KMsd, "iTRAQ-based quantitative proteomic analysis of differentially expressed proteins in chemoresistant nasopharyngeal carcinoma", Cancer Biol Ther, 19, pp.1~16 (2018)
- Bensouda Y, "Treatment for metastatic nasopharyngeal carcinoma", Eur Ann Otorhinolaryngol Head Neck Dis, 128, pp.79~85 (2011)
- Yu C, "Targeting FoxM1 inhibits proliferation, invasion and migration of nasopharyngeal carcinoma through the epithelialto-mesenchymal transition pathway", Oncol Rep, 33, pp.2402~2410 (2015)
- Jiang L, "Overexpression of FOXM1 is associated with metastases of nasopharyngeal carcinoma", Ups J Med Sci, 119, pp.324~332 (2014)
- San Filippo J, "Mechanism of eukaryotic homologous recombination", Annu Rev Biochem, 77, pp.229~257 (2008)
- Tauchi H, "Nbs1 is essential for DNA repair by homologous recombination in higher vertebrate cells", Nature, 420, pp.93~98 (2002)
- Nestal de Moraes G, "Insights into a critical role of the FOXO3a-FOXM1 axis in DNA damage response and genotoxic drug resistance", Curr Drug Targets, 17, pp.164~177 (2016)
- Rocha CRR, "DNA repair pathways and cisplatin resistance: an intimate relationship", Clinics (Sao Paulo), 73, pp.e478s~ (2018)
- Salehan MR, "DNA damage repair and tolerance : a role in chemotherapeutic drug resistance", Br J Biomed Sci, 70, pp.31~40 (2013)
- Jiang L, "Down-regulation of FoxM1 by thiostrepton or small interfering RNA inhibits proliferation, transformation ability and angiogenesis, and induces apoptosis of nasopharyngeal carcinoma cells", Int J Clin Exp Pathol, 7, pp.5450~5460 (2014)
- Zheng J, "Functional NBS1polymorphism is associated with occurrence and advanced disease status of nasopharyngeal carcinoma", Mol Carcinog, 50, pp.689~696 (2011)
- Jiang L, "Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma", J Cancer Res Clin Oncol, 141, pp.971~981 (2015)
- Ziebarth AJ, "Endoglin(CD105)contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer", Clin Cancer Res, 19, pp.170~182 (2013)